Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
15 Junho 2022 - 5:00PM
Company announcement – No.
29 /
2022
Transactions in Zealand Pharma
A/S securities by persons discharging
managerial responsibilities
Copenhagen, DK and Boston, MA, June 15, 2022 –
Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50
78), a Copenhagen-based biotechnology company focused on the
discovery and development of innovative peptide-based medicines,
announces that it has received information on transactions in
Zealand shares or related securities by persons discharging
managerial responsibilities.
Please see the attached files.
# # #
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In the US Zealand markets
V-Go®, a basal-bolus insulin delivery option for people with
diabetes, and Zegalogue®, (dasiglucagon), the first and only
glucagon analogue for the treatment severe hypoglycemia in
pediatric and adult patients with diabetes aged 6 and above.
License collaborations with Boehringer Ingelheim and AstraZeneca
create opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.
Zealand was founded in 1998 in Copenhagen,
Denmark, and has presence throughout the U.S. that includes key
locations in Boston, and Marlborough (MA). For more information
about Zealand’s business and activities, please
visit http://www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events. Such forward-looking
statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially
from expectations set forth herein and may cause any or all of such
forward-looking statements to be incorrect. If any or all of such
forward-looking statements prove to be incorrect, our actual
results could differ materially and adversely from those
anticipated or implied by such statements. All such forward-looking
statements speak only as of the date of this release and are based
on information available to Zealand Pharma as of the date of this
release.
For further information, please contact:
Zealand Pharma Investor RelationsMaeve
ConneightonArgot Partnersinvestors@zealandpharma.com
Zealand Pharma Media RelationsDavid RosenArgot
Partnersmedia@zealandpharma.com
- 73_220613_Notification_ASteensberg_psu
- 74_220613_Notification_IMøller_psu
Zealand Pharma AS (NASDAQ:ZEAL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zealand Pharma AS (NASDAQ:ZEAL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024